Skip to main content
Welcome to
Sanofi
About us
About us
U.S. LEADERSHIP
Our Stories
Corporate Compliance
Corporate Compliance
California Compliance Law
Shannon Kelley
California Compliance Law - Sanofi Pasteur
Compliance Program for Sanofi Pasteur
Committed to Transparency
Sanofi Websites in the U.S.
Your Health
Your Health
Vaccines
Science & Innovation
Science & Innovation
Clinical Trials
INVESTIGATOR SPONSORED STUDIES (ISS)
Products & Resources
Products & Resources
Prescription Products
Vaccines Products
Vaccines Products
Yellow Fever Vaccine Information
Generics
Consumer Health (OTC) Products
U.S. Patents
Patient Support Services
Resources for Healthcare Providers
Colorado Disclosure
Vermont Disclosure
Our Responsibility
Our Responsibility
Corporate Social Responsibility
Access to Healthcare
Patient Advocacy at Sanofi in the U.S.
Patient Advocacy at Sanofi in the U.S.
Health Equity at Sanofi in the U.S.
2023 Health Equity Accelerator Awards: Application Guidelines
2022 Health Equity Accelerator Award Winners
Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact
Patient Centered Healthcare Value Assessment
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
A Million Conversations: Addressing Disparities in Healthcare
Diversity in Clinical Trials
Employee Resource Groups
Supplier Diversity
Contributions and Giving
Contributions and Giving
TORCH Awards
Sponsorships
Philanthropic Donations
Healthcare Contributions
Independent Medical Education (IME/CME) Grants
Fellowships
Rare Genetic Disease Fellowships
Patient Assistance Foundations
Pricing Principles
Pricing Principles
2023 Pricing Principles Report
Clear Rationale for Pricing
Limited U.S. Price Increases
Continued Transparency in the U.S.
Prioritizing Patient Affordability
Healthy Planet
Careers
Careers
Benefits
Diversity
Postdoctoral Careers
Physician Careers
Students
Veterans
Investors
Media
Toggle navigation
Home
Press Releases
Subscribe
Social Media
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Sep 6, 2022
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 2, 2022
Provention Bio Announces the Grant of Inducement Awards
Aug 31, 2022
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
Aug 31, 2022
Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
Aug 30, 2022
FDA grants priority review to efanesoctocog alfa for people with hemophilia A
Show
5
10
25
50
100
per page
«
1
…
8
9
10
11
12
13
14
…
222
»
Print
Email page
RSS
